Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 2/20 | 0.49 |
| ▸ | MLKL | Q8NB16 | 5/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | COMT | P21964 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12065306 | 0.86 | MTOR (0.43) | CHEK2MLKLMEN1KMT2APDE10A | |
| SCHEMBL14770690 | 0.86 | MLKL (0.52) | CHEK2MLKLMTNR1BMTNR1ANPC1 | |
| SCHEMBL12066577 | 0.83 | MLKL (0.59) | CHEK2MLKLNPC1MEN1KMT2A | |
| SCHEMBL14770701 | 0.83 | MLKL (0.49) | CHEK2MLKLMTNR1BMTNR1AMEN1 | |
| SCHEMBL14770699 | 0.82 | MLKL (0.46) | CHEK2MLKLMTNR1BMTNR1ANPC1 | |
| SCHEMBL14770608 | 0.81 | MLKL (0.48) | CHEK2MLKLMTNR1BMTNR1AMEN1 | |
| SCHEMBL14770470 | 0.81 | MLKL (0.48) | CHEK2MLKLMTNR1BMTNR1AMEN1 | |
| SCHEMBL14770697 | 0.81 | MLKL (0.51) | CHEK2MLKLMTNR1BMTNR1AMEN1 | |
| SCHEMBL14770471 | 0.80 | MEN1 (0.55) | CHEK2MLKLMTNR1BMTNR1ANPC1 | |
| SCHEMBL14770512 | 0.79 | MEN1 (0.51) | MLKLNPC1MEN1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096531-B2 | Fused imidazole derivative | TOA EIYO LTD. (JP) | 2015-08-04 | — | — | US | disclosed |
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | TOA EIYO LTD. (JP) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | CACNA1E, CACNA1G, CACNA1A | CHEK2 1636/4885MLKL 2378/4885GSK3B 3938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.